H.C. Wainwright analyst Oren Livnat has reiterated their bullish stance on GRCE stock, giving a Buy rating on February 11.
Oren Livnat has given his Buy rating due to a combination of factors that highlight the promising potential of Grace Therapeutics’ GTX-104. The pivotal safety results from the STRIVE-ON study demonstrated that GTX-104, an intravenous nimodipine for treating aneurysmal subarachnoid hemorrhage (aSAH), showed favorable safety compared to the standard oral nimodipine. The study revealed a significant reduction in clinically meaningful hypotension events and improvements in dose intensity, which are crucial for better patient outcomes.
Further supporting the Buy recommendation, the data indicated that GTX-104 could lead to better recovery rates and fewer ICU readmissions. Despite a higher number of deaths in the GTX-104 group, the imbalance in the severity of patients’ conditions accounts for this difference, and no deaths were attributed to the therapy itself. The strong evidence of commercial potential and the likelihood of GTX-104 becoming a new gold standard in post-surgical aSAH care contribute to the positive outlook. The analyst anticipates a mid-year NDA filing and projects a launch in mid-2026, reinforcing confidence in the stock’s future performance.
In another report released on February 11, Craig-Hallum also reiterated a Buy rating on the stock with a $11.00 price target.